Julie Dawn Bolin

Eye on U — From Survival to Service

Abstract placeholder. Drop in the official SNMMI session abstract once published.

Day and time to be confirmed against the SNMMI program.

1. What's the actual bottleneck right now, isotopes, hot cells, or trained technologists?
2. Where do you see PSMA-targeted therapy hitting its real ceiling, clinical or operational?
3. How are you handling dosimetry standardization across sites in your trials?

Generated by a mock model. Wired to Anthropic when the API key is in place.

What we're seeing

• FierceBiotech · 2026-07-22
  Julie Dawn Bolin cited in NEJM perspective on theranostic standardization
  Coverage notes the company's growing footprint in the radioligand therapy space.
• BioPharma Reporter · 2026-08-17
  Julie Dawn Bolin joins editorial board of European Journal of Nuclear Medicine
  Details remain limited but analysts read the move as a positioning play ahead of pivotal data.
• Reuters Health · 2026-09-20
  Julie Dawn Bolin presents updated trial data at ASCO Annual Meeting
  Industry observers expect more activity of this kind in the run-up to SNMMI 2026.
• Endpoints News · 2026-02-03
  Julie Dawn Bolin co-authors review on PSMA in Journal of Nuclear Medicine
  The announcement comes amid tightening Mo-99 and Lu-177 supply.

Mocked while we wire the Exa integration. Headlines are illustrative.